<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02790710</url>
  </required_header>
  <id_info>
    <org_study_id>7293 (OCD)</org_study_id>
    <nct_id>NCT02790710</nct_id>
  </id_info>
  <brief_title>Brief Intervention for OCD Fears</brief_title>
  <official_title>Brief Intervention for OCD Fears</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will test the efficacy of propranolol or placebo, administered after reactivation
      of a previously acquired obsessive-compulsive disorder (OCD) fear, in reducing fear and
      avoidance in OCD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Twenty subjects with OCD will be enrolled in the study. Participants will complete baseline
      assessments of fear and avoidance. Participants will be randomly assigned to a single dose of
      propranolol 40mg or placebo, administered immediately after a fear reactivation procedure.
      Primary outcome assessment will be OCD symptoms and avoidance behavior in a behavioral
      avoidance task 2 weeks after the intervention
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Study has been suspended due to reconsideration of study design.
  </why_stopped>
  <start_date type="Actual">June 2016</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Yale Brown Obsessive-Compulsive Scale</measure>
    <time_frame>2 weeks</time_frame>
    <description>Total score on this Clinician-administered measure of OCD symptoms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Behavioral Avoidance Task</measure>
    <time_frame>2 weeks</time_frame>
    <description>Total number of steps completed (0-5) on this task assessing avoidance of OCD triggers</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Obsessive-compulsive Disorder</condition>
  <arm_group>
    <arm_group_label>Propanolol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Propranolol 40 mg capsule, given once after fear reactivation procedure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo capsule</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsule, given once after fear reactivation procedure</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propanolol</intervention_name>
    <description>Active treatment</description>
    <arm_group_label>Propanolol</arm_group_label>
    <other_name>Inderal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo capsule</arm_group_label>
    <other_name>sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Principal Diagnosis of Obsessive-Compulsive Disorder

        Exclusion Criteria:

          -  History of other serious psychiatric disorder

          -  Current Major Depressive Disorder

          -  Women who are pregnant or nursing

          -  Current use of psychiatric medication

          -  Persons planning to start another treatment during the study period

          -  Any significant medical condition that might increase the risk or participation or use
             of medications that might negatively interact with propranolol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Blair Simpson, MD</last_name>
    <role>Study Director</role>
    <affiliation>New York State Psychiatric Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York State Psychiatric Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10028-2611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 26, 2016</study_first_submitted>
  <study_first_submitted_qc>June 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2016</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>New York State Psychiatric Institute</investigator_affiliation>
    <investigator_full_name>Franklin Schneier</investigator_full_name>
    <investigator_title>Research Scientist</investigator_title>
  </responsible_party>
  <keyword>propanolol</keyword>
  <keyword>obsessive-compulsive disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Compulsive Personality Disorder</mesh_term>
    <mesh_term>Obsessive-Compulsive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propranolol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

